Articles in Scholarly Journals [Incomplete List]

1. Determination of ruthenium originating from the investigational anti-cancer drug NAMI-A in human plasma ultrafiltrate, plasma, and urine by inductively coupled plasma mass spectrometry
   Rapid Communications in Mass Spectrometry, vol. 21, no. 9, pp. 1521–1530, 2007
2. Liquid chromatography–tandem mass spectrometric assay for the nucleoside reverse transcriptase inhibitor emtricitabine in human plasma
   Biomedical Chromatography, vol. 21, no. 6, pp. 621–627, 2007
3. Validated assay for the simultaneous determination of the anti-cancer agent gemcitabine and its metabolite 2',2'-difluorodeoxyuridine in human plasma by high-performance liquid chromatography with tandem mass spectrometry
   Rapid Communications in Mass Spectrometry, vol. 21, no. 14, pp. 2312–2322, 2007
4. Severe pulmonary toxicity in patients with leiomyosarcoma after treatment with gemcitabine and docetaxel
   Investigational New Drugs, vol. 25, no. 3, pp. 279–281, 2007
5. Human mass balance study of the novel anticancer agent ixabepilone using accelerator mass spectrometry
   Investigational New Drugs, vol. 25, no. 4, pp. 327–334, 2007
6. Determination of imatinib mesylate and its main metabolite (CGP74588) in human plasma and murine specimens by ion-pairing reversed-phase high-performance liquid chromatography
   Biomedical Chromatography, vol. 21, no. 7, pp. 747–754, 2007
7. Novel paclitaxel formulations for oral application: a phase I pharmacokinetic study in patients with solid tumours
   Cancer Chemotherapy and Pharmacology, vol. 60, no. 5, pp. 635–642, 2007
8. Is rectal administration an alternative route for imatinib?
   Cancer Chemotherapy and Pharmacology, vol. 60, no. 4, pp. 623–624, 2007
9. Monitoring of platinum surface contamination in seven Dutch hospital pharmacies using inductively coupled plasma mass spectrometry
   International Archives of Occupational and Environmental Health, vol. 80, no. 8, pp. 689–699, 2007
10. The role of nuclear receptors in pharmacokinetic drug–drug interactions in oncology
    Cancer Treatment Reviews, vol. 33, no. 4, pp. 369–380, 2007
11. Phase I and pharmacokinetic trial of AP5346, a DACH–platinum–polymer conjugate, administered weekly for three out of every 4 weeks to advanced solid tumor patients
    Cancer Chemotherapy and Pharmacology, vol. 60, no. 4, pp. 523–533, 2007
12. Rationale and clinical application of alkylphospholipid analogues in combination with radiotherapy
    Cancer Treatment Reviews, vol. 33, no. 2, pp. 191–202, 2007
13. Enzymatic digestion as a tool for the LC–MS/MS quantification of large peptides in biological matrices: Measurement of chymotryptic fragments from the HIV-1 fusion inhibitor enfuvirtide and its metabolite M-20 in human plasma
    Journal of Chromatography B, vol. 854, no. 1-2, pp. 245–259, 2007
14. Liquid chromatography–tandem mass spectrometric assays for salinomycin in mouse plasma, liver, brain and small intestinal contents and in OptiMEM cell culture medium
    Journal of Chromatography B, vol. 855, no. 2, pp. 200–210, 2007
15. Stability experiments in human urine with EO9 (apaziquone): A novel anticancer agent for the intravesical treatment of bladder cancer
    Journal of Pharmaceutical and Biomedical Analysis, vol. 43, no. 1, pp. 285–292, 2007
16. Validation of SELDI-TOF MS serum protein profiles for renal cell carcinoma in new populations
    Laboratory Investigation, vol. 87, no. 2, Article ID 3700503, 11 pages, 2007
17. Pharmacogenetic Screening of the Gene Deletion and Duplications of CYP2D6
    Drug Metabolism Reviews, vol. 39, no. 1, pp. 45–60, 2007
18. Phase I Pharmacokinetic and Pharmacodynamic Study of the Oral Protein Kinase C  -Inhibitor Enzastaurin in Combination with Gemcitabine and Cisplatin in Patients with Advanced Cancer
    Clinical Cancer Research, vol. 13, no. 15, pp. 4474–4481, 2007
19. CYP2C9 and CYP2C19 Polymorphic Forms Are Related to Increased Indisulam Exposure and Higher Risk of Severe Hematologic Toxicity
    Clinical Cancer Research, vol. 13, no. 10, pp. 2970–2976, 2007
20. A Phase I, Randomized, Open-Label, Parallel-Cohort, Dose-Finding Study of Elacridar (GF120918) and Oral Topotecan in Cancer Patients
    Clinical Cancer Research, vol. 13, no. 11, pp. 3276–3285, 2007
21. Phase I Pharmacokinetic Study of the Safety and Tolerability of Lapatinib (GW572016) in Combination with Oxaliplatin/Fluorouracil/Leucovorin (FOLFOX4) in Patients with Solid Tumors
    Clinical Cancer Research, vol. 13, no. 15, pp. 4495–4502, 2007
22. A Phase I Safety and Pharmacologic Study of a Twice Weekly Dosing Regimen of the Oral Taxane BMS-275183
    Clinical Cancer Research, vol. 13, no. 13, pp. 3906–3912, 2007
23. Capecitabine
    The Oncologist, vol. 12, no. 2, pp. 152–155, 2007
24. Clinical and Pharmacologic Study of the Farnesyltransferase Inhibitor Tipifarnib in Cancer Patients With Normal or Mildly or Moderately Impaired Hepatic Function
    Journal of Clinical Oncology, vol. 24, no. 28, pp. 4558–4564, 2006
25. Genetic Polymorphisms of Drug Metabolising Enzymes and Drug Transporters in Relation to Cancer Risk
    Current Cancer Therapy Reviews, vol. 2, no. 2, pp. 137–155, 2006
26. Determinants of the elimination of methotrexate and 7-hydroxy-methotrexate following high-dose infusional therapy to cancer patients
    British Journal of Clinical Pharmacology, vol. 62, no. 1, pp. 71–80, 2006
27. Symptoms and Treatment in Cancer Therapy-Induced Early Menopause
    The Oncologist, vol. 11, no. 6, pp. 641–654, 2006
28. Herb-Drug Interactions in Oncology: Focus on Mechanisms of Induction
    The Oncologist, vol. 11, no. 7, pp. 742–752, 2006
29. Photodynamic Therapy in Oncology
    The Oncologist, vol. 11, no. 9, pp. 1034–1044, 2006
30. Saturable binding of indisulam to plasma proteins and distribution to human erythrocytes
    Drug Metabolism and Disposition, 2006
31. Relationship Between Cisplatin Administration and the Development of Ototoxicity
    Journal of Clinical Oncology, vol. 24, no. 6, pp. 918–924, 2006
32. Dose-Finding Phase I Clinical and Pharmacokinetic Study of Orally Administered Irinotecan in Patients with Advanced Solid Tumors
    Clinical Cancer Research, vol. 12, no. 12, pp. 3774–3781, 2006
33. Use of P-glycoprotein and BCRP inhibitors to improve oral bioavailability and CNS penetration of anticancer drugs
    Trends in Pharmacological Sciences, vol. 27, no. 1, pp. 17–24, 2006
34. The Effect of Low pH on Breast Cancer Resistance Protein (ABCG2)-Mediated Transport of Methotrexate, 7-Hydroxymethotrexate, Methotrexate Diglutamate, Folic Acid, Mitoxantrone, Topotecan, and Resveratrol in In Vitro Drug Transport Models
    Molecular Pharmacology, vol. 71, no. 1, pp. 240–249, 2006
35. Mass Balance Studies, with a Focus on Anticancer Drugs
    Clinical Pharmacokinetics, vol. 45, no. 1, pp. 33–58, 2006
36. Genetic Polymorphisms of Drug-Metabolising Enzymes and Drug Transporters in the Chemotherapeutic Treatment of Cancer
    Clinical Pharmacokinetics, vol. 45, no. 3, pp. 253–285, 2006
37. Pharmacogenetic Screening of CYP3A and ABCB1 in Relation to Population Pharmacokinetics of Docetaxel
    Clinical Cancer Research, vol. 12, no. 19, pp. 5786–5793, 2006
38. Flat Dosing of Carboplatin Is Justified in Adult Patients with Normal Renal Function
    Clinical Cancer Research, vol. 12, no. 21, pp. 6502–6508, 2006
39. Interactions of Serum Albumin, Valproic Acid and Carbamazepine with the Pharmacokinetics of Phenytoin in Cancer Patients
    Basic Clinical Pharmacology Toxicology, vol. 99, no. 2, pp. 133–140, 2006
40. Analytical Chemistry, vol. 78, no. 8, pp. 2617–2622, 2006
41. Adduct-specific monoclonal antibodies for the measurement of cisplatin-induced DNA lesions in individual cell nuclei
    Nucleic Acids Research, vol. 34, no. 6, pp. e47–e47, 2006
42. Carcinogen and Anticancer Drug Transport by Mrp2 in Vivo: Studies Using Mrp2 (Abcc2) Knockout Mice
    Journal of Pharmacology and Experimental Therapeutics, vol. 318, no. 1, pp. 319–327, 2006
43. Radiosensitization of Squamous Cell Carcinoma by the Alkylphospholipid Perifosine in Cell Culture and Xenografts
    Clinical Cancer Research, vol. 12, no. 5, pp. 1615–1622, 2006
44. Quantitative Effect of Gender, Age, Liver Function, and Body Size on the Population Pharmacokinetics of Paclitaxel in Patients with Solid Tumors
    Clinical Cancer Research, vol. 12, no. 7, pp. 2150–2157, 2006
45. A novel self-microemulsifying formulation of paclitaxel for oral administration to patients with advanced cancer
    British Journal of Cancer, vol. 95, no. 6, Article ID 6603312, 5 pages, 2006
46. Phase II and pharmacological study of oral paclitaxel (Paxoral) plus ciclosporin in anthracycline-pretreated metastatic breast cancer
    British Journal of Cancer, vol. 95, no. 7, Article ID 6603332, 6 pages, 2006
47. Clinical proteomics: searching for better tumour markers with SELDI-TOF mass spectrometry
    Trends in Pharmacological Sciences, vol. 27, no. 5, pp. 251–259, 2006
48. Phase I and pharmacokinetic study of combined treatment with perifosine and radiation in patients with advanced solid tumours
    Radiotherapy and Oncology, vol. 80, no. 2, pp. 207–213, 2006
49. Absolute quantification of farnesylated Ras levels in complex samples using liquid chromatography fractionation combined with tryptic digestion and electrospray tandem mass spectrometry
    Analytical Biochemistry, vol. 352, no. 1, pp. 33–40, 2006
50. Future opportunities in preventing cisplatin induced ototoxicity
    Cancer Treatment Reviews, vol. 32, no. 5, pp. 390–397, 2006
51. Validation of in vitro cell models used in drug metabolism and transport studies; genotyping of cytochrome P450, phase II enzymes and drug transporter polymorphisms in the human hepatoma (HepG2), ovarian carcinoma (IGROV-1) and colon carcinoma (CaCo-2, LS180) cell lines
    Toxicology and Applied Pharmacology, vol. 211, no. 1, pp. 1–10, 2006
52. Screening for polymorphisms in the PXR gene in a Dutch population
    European Journal of Clinical Pharmacology, vol. 62, no. 5, pp. 395–399, 2006
53. A Semi-Physiological Population Pharmacokinetic Model Describing the Non-linear Disposition of Indisulam
    Journal of Pharmacokinetics and Pharmacodynamics, vol. 33, no. 5, pp. 543–570, 2006
54. Metabolism of trabectedin (ET-743, Yondelis™) in patients with advanced cancer
    Cancer Chemotherapy and Pharmacology, vol. 59, no. 6, pp. 825–837, 2006
55. The pharmacokinetic behavior of the photosensitizer meso-tetra-hydroxyphenyl-chlorin in mice and men
    Cancer Chemotherapy and Pharmacology, vol. 60, no. 1, pp. 113–122, 2006
56. A pharmacokinetic and safety study of a novel polymeric paclitaxel formulation for oral application
    Cancer Chemotherapy and Pharmacology, vol. 59, no. 1, pp. 43–50, 2006
57. Novel deoxycytidine kinase gene polymorphisms: a population screening study in Caucasian healthy volunteers
    European Journal of Clinical Pharmacology, vol. 62, no. 8, pp. 681–684, 2006
58. Liquid chromatography–tandem mass spectrometric assay for the analysis of uracil, 5,6-dihydrouracil and ß-ureidopropionic acid in urine for the measurement of the activities of the pyrimidine catabolic enzymes?
    Journal of Chromatography B, vol. 839, no. 1-2, pp. 45–53, 2006
59. Development and validation of a quantitative assay for the measurement of two HIV-fusion inhibitors, enfuvirtide and tifuvirtide, and one metabolite of enfuvirtide (M-20) in human plasma by liquid chromatography–tandem mass spectrometry
    Journal of Chromatography B, vol. 837, no. 1-2, pp. 49–58, 2006
60. Trabectedin (ET-743, Yondelis™) is a substrate for P-glycoprotein, but only high expression of P-glycoprotein confers the multidrug resistance phenotype
    Investigational New Drugs, vol. 25, no. 1, pp. 1–7, 2006
61. Phase I dose-finding and pharmacokinetic trial of orally administered indibulin (D-24851) to patients with solid tumors
    Investigational New Drugs, vol. 25, no. 3, pp. 227–235, 2006
62. In vitro characterization of the human biotransformation and CYP reaction phenotype of ET-743 (Yondelis®, Trabectidin®), a novel marine anti-cancer drug
    Investigational New Drugs, vol. 24, no. 1, pp. 3–14, 2006
63. In vitro characterization of the human biotransformation pathways of aplidine, a novel marine anti-cancer drug
    Investigational New Drugs, vol. 25, no. 1, pp. 9–19, 2006
64. The effect of hydroxyurea on P-glycoprotein/BCRP-mediated transport and CYP3A metabolism of imatinib mesylate
    Cancer Chemotherapy and Pharmacology, vol. 59, no. 6, pp. 855–860, 2006
65. Quantitative analysis of gemcitabine triphosphate in human peripheral blood mononuclear cells using weak anion-exchange liquid chromatography coupled with tandem mass spectrometry
    Journal of Mass Spectrometry, vol. 41, no. 12, pp. 1633–1642, 2006
66. Sensitive inductively coupled plasma mass spectrometry assay for the determination of platinum originating from cisplatin, carboplatin, and oxaliplatin in human plasma ultrafiltrate
    Journal of Mass Spectrometry, vol. 41, no. 9, pp. 1186–1194, 2006
67. Quantitative analysis of EO9 (apaziquone) and its metabolite EO5a in human plasma by high-performance liquid chromatography under basic conditions coupled to electrospray tandem mass spectrometry
    Journal of Mass Spectrometry, vol. 41, no. 10, pp. 1268–1276, 2006
68. Prediction of treatment outcome by cisplatin-DNA adduct formation in patients with stage III/IV head and neck squamous cell carcinoma, treated by concurrent cisplatin-radiation (RADPLAT)
    International Journal of Cancer, vol. 119, no. 4, pp. 750–756, 2006
69. Liquid chromatographic assay for the non-peptidic protease inhibitor tipranavir in plasma
    Biomedical Chromatography, vol. 20, no. 8, pp. 671–673, 2006
70. A rapid and simple HPLC-UV method for the determination of inhibition characteristics of farnesyl transferase inhibitors
    Biomedical Chromatography, vol. 20, no. 2, pp. 161–165, 2006
71. A simple and sensitive assay for the quantitative analysis of paclitaxel and metabolites in human plasma using liquid chromatography/tandem mass spectrometry
    Biomedical Chromatography, vol. 20, no. 1, pp. 139–148, 2005
72. Liquid chromatographic assay for the protease inhibitor atazanavir in plasma
    Biomedical Chromatography, vol. 20, no. 1, pp. 72–76, 2005
73. Quantitative analysis of docetaxel in human plasma using liquid chromatography coupled with tandem mass spectrometry
    Biomedical Chromatography, vol. 19, no. 5, pp. 355–361, 2005
74. Determination of oxaliplatin in human plasma and plasma ultrafiltrate by graphite-furnace atomic-absorption spectrometry
    Analytical and Bioanalytical Chemistry, vol. 382, no. 7, pp. 1484–1490, 2005
75. Quantitative analysis of the farnesyl transferase inhibitor lonafarnib (Sarasar™, SCH66336) in human plasma using high-performance liquid chromatography coupled with tandem mass spectrometry
    Rapid Communications in Mass Spectrometry, vol. 19, no. 15, pp. 2187–2192, 2005
76. Structure elucidation of aplidine metabolites formedin vitro by human liver microsomes using triple quadrupole mass spectrometry
    Journal of Mass Spectrometry, vol. 40, no. 6, pp. 821–831, 2005
77. Pharmacokinetics of low-dose doxorubicin and metabolites in patients with AIDS-related Kaposi sarcoma
    Cancer Chemotherapy and Pharmacology, vol. 55, no. 5, pp. 488–496, 2005
78. Metabolism of docetaxel in mice
    Cancer Chemotherapy and Pharmacology, vol. 56, no. 3, pp. 299–306, 2005
79. Absence of N-linked glycosylation does not affect plasma membrane localization of breast cancer resistance protein (BCRP/ABCG2)
    Cancer Chemotherapy and Pharmacology, vol. 56, no. 4, pp. 344–350, 2005
80. Tumor and normal tissue pharmacokinetics of perifosine, an oral anti-cancer alkylphospholipid
    Investigational New Drugs, vol. 23, no. 4, pp. 279–286, 2005
81. Human metabolism of [14C]indisulam following i.v. infusion in cancer patients
    Investigational New Drugs, vol. 23, no. 4, pp. 317–330, 2005
82. Trabectedin (YondelisTM, formerly ET-743), a mass balance study in patients with advanced cancer
    Investigational New Drugs, vol. 23, no. 5, pp. 429–436, 2005
83. Semi-physiological model describing the hematological toxicity of the anti-cancer agent indisulam
    Investigational New Drugs, vol. 23, no. 3, pp. 225–234, 2005
84. Hepatotoxicity and metabolism of trabectedin: a literature review
    Pharmacological Research, 2005
85. Chronic hepatotoxicity after long-term antiretroviral treatment including nevirapine
    Journal of Infection, vol. 50, no. 3, pp. 262–264, 2005
86. Phase I and pharmacological study of the farnesyltransferase inhibitor tipifarnib (Zarnestra®, R115777) in combination with gemcitabine and cisplatin in patients with advanced solid tumours
    British Journal of Cancer, vol. 93, no. 11, Article ID 6602850, 7 pages, 2005
87. Modulation of Oral Drug Bioavailability: From Preclinical Mechanism to Therapeutic Application
    Cancer Investigation, vol. 23, no. 5, pp. 443–464, 2005
88. No pharmacokinetic drug???drug interaction between nevirapine and paclitaxel
    Anti-Cancer Drugs, vol. 16, no. 6, pp. 627–630, 2005
89. Breast Cancer Resistance Protein (Bcrp1/Abcg2) Limits Net Intestinal Uptake of Quercetin in Rats by Facilitating Apical Efflux of Glucuronides
    Molecular Pharmacology, vol. 67, no. 6, pp. 1999–2006, 2005
90. Phase I Clinical and Pharmacokinetic Study of Kahalalide F in Patients with Advanced Androgen Refractory Prostate Cancer
    Clinical Cancer Research, vol. 11, no. 5, pp. 1854–1862, 2005
91. Phase I clinical and pharmacologic study of a 2-weekly administration of cisplatin and gemcitabine in patients with advanced non-small cell lung cancer
    Anti-Cancer Drugs, vol. 16, no. 9, pp. 1029–1036, 2005
92. In-vitro cytotoxicity of ET-743 (Trabectedin, Yondelis), a marine anti-cancer drug, in the Hep G2 cell line: influence of cytochrome P450 and phase II inhibition, and cytochrome P450 induction
    Anti-Cancer Drugs, vol. 16, no. 9, pp. 935–943, 2005
93. Population pharmacokinetics of orally administered paclitaxel formulated in Cremophor EL
    British Journal of Clinical Pharmacology, vol. 59, no. 3, pp. 325–334, 2005
94. Development of Farnesyl Transferase Inhibitors: A Review
    The Oncologist, vol. 10, no. 8, pp. 565–578, 2005
95. Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva(R)) and Gefitinib (Iressa(R))
    The Oncologist, vol. 10, no. 8, pp. 579–589, 2005
96. Cannulation of the jugular vein in mice
    Laboratory Animals, vol. 39, no. 1, pp. 130–132, 2005
97. MIDAZOLAM AND CYCLOSPORIN A METABOLISM IN TRANSGENIC MICE WITH LIVER-SPECIFIC EXPRESSION OF HUMAN CYP3A4
    Drug Metabolism and Disposition, vol. 33, no. 7, pp. 892–895, 2005
98. The Effect of Bcrp1 (Abcg2) on the In vivo Pharmacokinetics and Brain Penetration of Imatinib Mesylate (Gleevec): Implications for the Use of Breast Cancer Resistance Protein and P-Glycoprotein Inhibitors to Enable the Brain Penetration of Imatinib in Patients
    Cancer Research, vol. 65, no. 7, pp. 2577–2582, 2005
99. Individualised Cancer Chemotherapy: Strategies and Performance of Prospective Studies on Therapeutic Drug Monitoring with Dose Adaptation
    Clinical Pharmacokinetics, vol. 44, no. 2, pp. 147–173, 2005
100. Detection of Single Nucleotide Polymorphisms in the ABCG2 Gene in a Dutch Population
     American Journal of PharmacoGenomics, vol. 5, no. 2, pp. 123–131, 2005
101. Therapeutic drug monitoring of non-anticancer drugs in cancer patients
     Methods and Findings in Experimental and Clinical Pharmacology, vol. 26, no. 7, p. 531, 2004
102. A Phase I and Pharmacological Study of the Platinum Polymer AP5280 Given as an Intravenous Infusion Once Every 3 Weeks in Patients with Solid Tumors
     Clinical Cancer Research, vol. 10, no. 10, pp. 3386–3395, 2004
103. The Effect of Food on the Pharmacokinetics of S-1 after Single Oral Administration to Patients with Solid Tumors
     Clinical Cancer Research, vol. 10, no. 12, pp. 4072–4076, 2004
104. Mechanism of the Pharmacokinetic Interaction between Methotrexate and Benzimidazoles: Potential Role for Breast Cancer Resistance Protein in Clinical Drug-Drug Interactions
     Cancer Research, vol. 64, no. 16, pp. 5804–5811, 2004
105. Platinated DNA Adducts Enhance Poisoning of DNA Topoisomerase I by Camptothecin
     Journal of Biological Chemistry, vol. 279, no. 52, pp. 54502–54509, 2004
106. Bayesian Pharmacokinetically Guided Dosing of Paclitaxel in Patients with Non-Small Cell Lung Cancer
     Clinical Cancer Research, vol. 10, no. 7, pp. 2237–2244, 2004
107. A Phase I and Pharmacological Study with Imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a Novel Ruthenium Anticancer Agent
     Clinical Cancer Research, vol. 10, no. 11, pp. 3717–3727, 2004
108. Phase I Study of Docetaxel in Combination with the P-Glycoprotein Inhibitor, Zosuquidar, in Resistant Malignancies
     Clinical Cancer Research, vol. 10, no. 21, pp. 7220–7228, 2004
109. Drug interactions in oncology
     The Lancet Oncology, vol. 5, no. 8, pp. 489–496, 2004
110. Drug-Drug Interaction between Itraconazole and the Antiretroviral Drug Lopinavir/Ritonavir in an HIV-1-Infected Patient with Disseminated Histoplasmosis
     Clinical Infectious Diseases, vol. 38, no. 8, pp. e73–e75, 2004
111. Efficacy of novel P-glycoprotein inhibitors to increase the oral uptake of paclitaxel in mice
     Investigational New Drugs, vol. 22, no. 3, pp. 219–229, 2004
112. A randomised phase II multicentre trial of irinotecan (CPT-11) using four different schedules in patients with metastatic colorectal cancer
     British Journal of Cancer, Article ID 6602172, 2004
113. In vitro characterization of the biotransformation of thiocoraline, a novel marine anti-cancer drug
     Investigational New Drugs, vol. 22, no. 3, pp. 241–251, 2004
114. Pharmacokinetic Drug–Drug Interaction of the Novel Anticancer Agent E7070 and Acenocoumarol
     Investigational New Drugs, vol. 22, no. 2, pp. 151–158, 2004
115. No topoisomerase I alteration in a neuroblastoma model with in vivo acquired resistance to irinotecan
     British Journal of Cancer, Article ID 6602079, 2004
116. Isolated hepatic perfusion for the treatment of colorectal metastases confined to the liver: recent trends and perspectives
     European Journal of Cancer, vol. 40, no. 12, pp. 1812–1824, 2004
117. Development and validation of a method to determine the unbound paclitaxel fraction in human plasma
     Analytical Biochemistry, vol. 324, no. 1, pp. 11–15, 2004
118. Systemic and tumor disposition of platinum after administration of cisplatin or STEALTH liposomal-cisplatin formulations (SPI-077 and SPI-077 B103) in a preclinical tumor model of melanoma
     Cancer Chemotherapy and Pharmacology, vol. 53, no. 4, pp. 329–336, 2004
119. Quantitative analysis of the novel anticancer drug ABT-518, a matrix metalloproteinase inhibitor, plus the screening of six metabolites in human plasma using high-performance liquid chromatography coupled with electrospray tandem mass spectrometry
     Journal of Mass Spectrometry, vol. 39, no. 3, pp. 277–288, 2004
120. Cytotoxicity of the organic ruthenium anticancer drug Nami-A is correlated with DNA binding in four different human tumor cell lines
     Cancer Chemotherapy and Pharmacology, vol. 54, no. 1, pp. 71–78, 2004
121. Oral bioavailability of docetaxel in combination with OC144-093 (ONT-093)
     Cancer Chemotherapy and Pharmacology, vol. 55, no. 1, pp. 72–78, 2004
122. Phase I study of an oral formulation of irinotecan administered daily for 14?days every 3?weeks in patients with advanced solid tumours
     Cancer Chemotherapy and Pharmacology, vol. 55, no. 3, pp. 263–270, 2004
123. Quantitative analysis of the P-glycoprotein inhibitor Elacridar (GF120918) in human and dog plasma using liquid chromatography with tandem mass spectrometric detection
     Journal of Mass Spectrometry, vol. 39, no. 10, pp. 1122–1130, 2004
124. Quantitative determination of the novel anticancer drug E7070 (indisulam) and its metabolite (1,4-benzenedisulphonamide) in human plasma, urine and faeces by high-performance liquid chromatography coupled with electrospray ionization tandem mass spectrometry
     Rapid Communications in Mass Spectrometry, vol. 18, no. 23, pp. 2839–2848, 2004
125. Quantitative analysis of D-24851, a novel anticancer agent, in human plasma and urine by liquid chromatography coupled with tandem mass spectrometry
     Rapid Communications in Mass Spectrometry, vol. 18, no. 13, pp. 1465–1471, 2004
126. A more sensitive MS detector does not obviously lead to a more sensitive assay: experiences with ES-285
     Biomedical Chromatography, vol. 18, no. 6, pp. 403–407, 2004
127. Switching from an analogous to a stable isotopically labeled internal standard for the LC-MS/MS quantitation of the novel anticancer drug Kahalalide F signi?cantly improves assay performance
     Biomedical Chromatography, vol. 18, no. 6, pp. 400–402, 2004
128. Liquid chromatographic assay for the cyclic depsipeptide aplidine, a new marine antitumor drug, in whole blood using derivatization withtrans-4'-hydrazino-2-stilbazole
     Biomedical Chromatography, vol. 18, no. 1, pp. 16–20, 2004
129. Simple high-performance liquid chromatographic assay for melphalan in perfusate, rat liver and tumour tissue
     Biomedical Chromatography, vol. 17, no. 7, pp. 458–464, 2003
130. Quantitative analysis of ES-285, an investigational marine anticancer drug, in human, mouse, rat, and dog plasma using coupled liquid chromatography and tandem mass spectrometry
     Journal of Mass Spectrometry, vol. 38, no. 5, pp. 548–554, 2003
131. An update on in vitro test methods in human hepatic drug biotransformation research: pros and cons
     Toxicology and Applied Pharmacology, vol. 189, no. 3, pp. 233–246, 2003
132. Investigational New Drugs, vol. 21, no. 2, pp. 225–241, 2003
133. Liquid chromatographic assay for the antiviral nucleotide analogue tenofovir in plasma using derivatization with chloroacetaldehyde
     Journal of Chromatography B, vol. 791, no. 1-2, pp. 227–233, 2003
134. DNA repair mechanisms involved in gemcitabine cytotoxicity and in the interaction between gemcitabine and cisplatin
     Biochemical Pharmacology, vol. 65, no. 2, pp. 275–282, 2003
135. Phase I clinical and pharmacokinetic study of E7070, a novel sulfonamide given as a 5-day continuous infusion repeated every 3 weeks in patients with solid tumours. A study by the EORTC Early Clinical Study Group (ECSG)
     European Journal of Cancer, vol. 39, no. 8, pp. 1097–1104, 2003
136. Phase II trial with S-1 in chemotherapy-naïve patients with gastric cancer. A trial performed by the EORTC Early Clinical Studies Group (ECSG)
     European Journal of Cancer, vol. 39, no. 9, pp. 1264–1270, 2003
137. EORTC Early Clinical Studies Group early phase II trial of S-1 in patients with advanced or metastatic colorectal cancer
     British Journal of Cancer, vol. 88, no. 5, Article ID 6600781, 5 pages, 2003
138. Adaptive intrapatient dose escalation of cisplatin in combination with low-dose vp16 in patients with nonsmall cell lung cancer
     British Journal of Cancer, vol. 88, no. 6, Article ID 6600794, 7 pages, 2003
139. A population pharmacokinetic model for paclitaxel in the presence of a novel P-gp modulator, Zosuquidar Trihydrochloride (LY335979)
     British Journal of Clinical Pharmacology, vol. 56, no. 1, pp. 46–56, 2003
140. Erratum
     British Journal of Clinical Pharmacology, vol. 56, no. 4, pp. 463–463, 2003
141. Evidence for Two Interacting Ligand Binding Sites in Human Multidrug Resistance Protein 2 (ATP Binding Cassette C2)
     Journal of Biological Chemistry, vol. 278, no. 26, pp. 23538–23544, 2003
142. Weekly oral paclitaxel as first-line treatment in patients with advanced gastric cancer
     Annals of Oncology, vol. 14, no. 2, pp. 197–204, 2003